CyclingA villainius-based startup focuses on the development of innovative treatment for people in the face of mental health challenges, raising more than $ 500k in the pre-margin investment round.
The VC Fund, led by this round, was run by Coinvest Capital, participating in FirstPic and BSVO, as well as with Angel investors’ syndicate.
“In cycling, we are developing science -based therapy inspired by nature to help them not benefit from conventional treatment. We are proud to be partners with investors who recognize the emergency and possibility of this job. Our multi -division team is combined with a clear mission: to create safe, effective and sustainable solutions for mental health, drawing on the rich variations of bioactive compounds found in plants and fungi“Said LauraCEO SISLink is the chief executive officer.
Established in 2021, Sicillink is a biotech company that focuses on developing innovative treatment for mental health disorders. Its research and development techniques are built on two main pillars. Cyclicink is developing a sustainable biotechnology platform to produce natural compounds, especially fungus-molecules, engineering East cells are used as biosintic “min-factor”. The goal of this approach is to provide environmentally friendly alternatives to the traditional chemical synthesis and drainage processes.
The second pillar focuses on discovery and evaluation of fancy compounds for conditions like disappointment and PTSD. By studying silosbin and related fungi, cycling is to reveal new therapeutic agents through deep understanding of their molecular interactions and influences on cellular systems.
“Cycling stands in combination with strict biotechnology with the possibilities of the treatment of natural compounds – a method that is based on not only innovative but also on the basis of strong scientific validity. What fascinated us is the traditional knowledge and their ability to bridge modern neuroscience. It requires the invention of this type of converter in the emotional health care market, and we believe that cycling is well-located to lead in this emerging place,” VictorManaging Director of Coinvest Capital, mentioned.
The capital will be used to advance the biotechnology platform owned by cycling for sustainable production of plant- and fungal compounds. It will further enhance the screening and evaluation of the novel’s molecular candidates, accelerating the detection of high-deficient compounds for further development and pre-discrimination validity.
“The work of cycling with the next generation of cyclylik derivatives is likely to be new to patients in the face of mental health challenges. I am respected to support the team in this early stage and to help bring these most essential therapies to those who are most needed,“Said ErinLeadership of Angel Investor Syndicate.
Cycleing outline has revealed that they were established to deal with a critical gap in the mental health care market by developing fancy treatment for patients who did not respond to conventional therapy.
There is an estimated 30-40% of the more effective, science-driven options in demand for the minimal or not getting any benefits from standard antidepressants-a goal is to lead cycling a region.
“Sicillink is a rare example of dipTech innovation from our region, adding a global challenge with scientific precision and purpose. We are proud to support a genuine biotek developer with the possibility of transforming how we treat mental health“Comment SandraPartner in BSV Venture.
[publish_date
